Form 4: RAPT Therapeutics Director Lori Lyons-Williams Granted Stock Options

RAPT Therapeutics, Inc. Director Lori Lyons-Williams was granted 257,832 stock options with an exercise price of $0.93, vesting over 12 months.

Summary

• Lori Lyons-Williams, a Director of RAPT Therapeutics, Inc., was granted 257,832 Director Stock Options.
• The grant date for these options was May 29, 2025.
• The exercise price for the acquired options is $0.93 per share.
• The options are set to vest in 12 equal monthly installments, commencing from the grant date of May 29, 2025.
• The expiration date for these stock options is May 28, 2035.
• Following this reported transaction, Ms. Lyons-Williams beneficially owns 257,832 derivative securities.

Sentiment

Score: 7

Explanation: The document reports a standard equity grant to a director, which is a positive indicator of continued alignment between the board and shareholder interests, though it does not represent a significant new development for the company's operations or financial health.

Positives

• The grant of stock options to Director Lori Lyons-Williams aligns her financial interests with the long-term performance and shareholder value creation of RAPT Therapeutics, Inc.
• Equity compensation for directors is a standard corporate governance practice that incentivizes board members to contribute to the company's strategic growth and success.

Negatives

• No negative implications are directly evident from this routine equity grant, which is a standard form of director compensation.

Risks

• No specific risks are mentioned within this Form 4 filing, as it primarily serves as a report of an insider transaction.

Future Outlook

The grant of stock options to a director is a routine compensation event that implies continued alignment of the director's interests with the company's long-term performance and strategic objectives.

Industry Context

The grant of stock options to board members is a common and widely accepted practice within the biotechnology and pharmaceutical industries, serving as a key component of director compensation packages to attract and retain qualified individuals and align their incentives with shareholder value.

Comparison to Industry Standards

• The grant of stock options as a form of equity compensation for directors is a common and widely accepted practice across the biotechnology and pharmaceutical industries, aligning director incentives with long-term shareholder value creation. While specific comparable companies or projects are not detailed in this filing, this type of compensation structure is standard for board members in publicly traded life sciences companies.

Related Party Transactions

• The grant of stock options to Lori Lyons-Williams, a Director of RAPT Therapeutics, Inc., constitutes a related party transaction, which is a standard form of equity compensation for board members.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with long-term shareholder value.
• Director (Lori Lyons-Williams): Receives equity compensation, incentivizing her contribution to the company's success.

Next Steps

• The granted stock options will vest in 12 equal monthly installments from May 29, 2025, over the subsequent year.

Key Dates

Recommendation

Keywords

RAPT Therapeutics, RAPT, stock options, director compensation, insider transaction, Form 4, equity grant, beneficial ownership